Three-dimensional cultures (or “organoids”) derived from the tumors of cancer patients closely replicate key properties of the original tumors, reveals a study published May 7 in Cell. These “organoid” cultures are amenable to large-scale drug screens for the detection of genetic changes associated with drug sensitivity and pave the way for personalized treatment approaches that could optimize clinical outcomes in cancer patients.
“This is the first time that a collection of cancer organoids, or a living biobank, has been derived from patient tumors,” says senior study author Mathew Garnett, a geneticist at the Wellcome Trust Sanger Institute. “We believe that these organoids are an important new tool in the arsenal of cancer biologists and may ultimately improve our ability to develop more effective cancer treatments.”
To study the causes of cancer and develop new cancer treatments, many laboratories use experimental model systems such as cells grown from patient tumors. However, currently available cell lines have been derived under suboptimal conditions and therefore fail to reflect important features of tumor cells. As a result, it has been challenging to predict the drug sensitivity of individual patients based on their unique spectrum of genetic mutations.
In recent years, scientists have developed organoid cell culture systems as an alternative approach to grow normal and diseased tissue in a dish. In contrast to cell lines, organoids display the hallmarks of the original tissue in terms of its 3D architecture, the cell types present, and their self-renewal properties. Given the advantages of organoids, Garnett and Hans Clevers of the Hubrecht Institute set out to test whether these cultures could potentially bridge the gap between cancer genetics and patient outcomes.
In the new study, the researchers grew 22 organoids derived from tumor tissue from 20 patients with colorectal cancer and then sequenced genomic DNA isolated from these cultures. The genetic mutations in the organoid cultures closely matched those in the corresponding tumor biopsies and agreed well with previous large-scale analyses of colorectal cancer mutations. These findings confirm that the cultures faithfully capture the genomic features of the tumors from which they are derived as well as much of the genomic diversity associated with colorectal cancer.
To link drug sensitivity to genetic changes, the researchers next screened the responses of the organoids to 83 experimental and approved cancer drugs. Given their diverse genetic profiles, the organoids displayed a range of sensitivities to the drugs. In validation of the approach, the researchers identified previously reported associations between specific mutations and resistance to particular drugs. The organoids also revealed a novel gene-drug association, indicating that the subset of cancer patients with RNF43 mutations would strongly benefit from a drug that inhibits a protein called porcupine. “At some point in the future, this approach may be suitable for modeling individual patient response to cancer therapies to inform clinical treatment,” Garnett says.
The Latest on: Organoids
via Google News
The Latest on: Organoids
- Low Drug Discovery Driving Organoids Sales, Especially Intestinal Organoids: FMI Researchon October 12, 2021 at 11:15 pm
Organoids are three-dimensional (3D) structures that resemble mammalian organs and are made from stem cells. As per a study by Future Market Insights (FMI), the global organoids market is estimated to ...
- MIT Spinoff Travera Looks to Validate Cell Mass as Broadly Predictive Cancer Biomarkeron October 12, 2021 at 2:50 pm
A recent study showed that the firm's technology could predict glioblastoma patients' chemo responses as well or better than an established genomic biomarker.
- Researchers Replicate Mini Human Lungs to Study Impact on RTIon October 11, 2021 at 11:40 pm
Concept: Researchers from the University of California San Diego (UCSD) have used adult stem cells to produce mini human lungs in lab dishes. Scientists intend to study how respiratory and infectious ...
- Global Organoids Market 2021 Growth, Trend, Analysis, Future Opportunities and Industry Forecast to 2027on October 5, 2021 at 6:59 pm
A research study conducted on Global Organoids Market 2021 by Company, Regions, Type and Application, Forecast ...
- Progress in the Genetics of Polygenic Brain Disorders: Significant New Challenges for Neurobiologyon October 4, 2021 at 3:17 pm
Advances in genome analysis, accompanied by the assembly of large patient cohorts, have made possible successful genetic analyses of polygenic brain disorders. If the resulting molecular clues, ...
- An Individual Patient's “Body” on Chips—How Organismoid Theory Can Translate Into Your Personal Precision Therapy Approachon October 2, 2021 at 5:00 pm
Marx et al. Frontiers in Medicine. The first concepts for reproducing human systemic organismal biology in vitro were developed over 12 years ago. Such concepts, then called human- or ...
- Engineers grow pancreatic “organoids” that mimic the real thingon September 22, 2021 at 12:29 pm
Using a specialized gel that mimics the extracellular environment surrounding the pancreas, the researchers were able to grow pancreatic “organoids,” allowing them to study the important interactions ...
- Study highlights the usefulness of organoids for basic research into coronaviruseson September 19, 2021 at 10:50 pm
Their study was published in Nature Communications on 17 September and highlights the usefulness of organoids for basic research into coronaviruses, as well as highlighting potential drug targets.
- When Organoids Meet Coronaviruses: Assessing Potential COVID Drug Targetson September 18, 2021 at 11:25 am
Researchers from the group of Hans Clevers in collaboration with the group of Bart Haagmans (Erasmus MC) established an organoid biobank to search for the genes that are essential for the spreading of ...
- When organoids meet coronaviruseson September 17, 2021 at 7:24 am
Their study highlights the usefulness of organoids for basic research into coronaviruses, as well as highlighting potential drug targets. Researchers from the group of Hans Clevers in ...
via Bing News